Aldeyra Therapeutics Stock (NASDAQ: ALDX)

Aldeyra Therapeutics

ALDEYRA THERAPEUTICS INC

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics Inc

Press Releases

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

ALDX

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Avalo Therapeutics

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lyell Immunopharma

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Palisade Bio

Puma Biotechnology

PepGen

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Aldeyra Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL